Brent P. Forester
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brent P. Forester has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
David G. Harper
Division of Geriatric Psychiatry, Geriatric Psychiatry Research Program (BPF, ATR, DGH), McLean Hospital, Belmont, MA; Department of Psychiatry, Harvard Medical School (BPF, DGH), Boston, MA
3 shared publicationsBruce M. Cohen
Department of Psychiatry, Harvard Medical School, Belmont, MA
2 shared publicationsCaitlin Ravichandran
Department of Psychiatry (DGH, CR, EJ, MS, BPF), Harvard Medical School, Boston; Program for Neuropsychiatric Research (CR), McLean Hospital, Belmont, MA; Lurie Center for Autism (CR), Massachusetts General Hospital, Lexington, MA
2 shared publicationsGary Epstein-Lubow
Hebrew SeniorLife (GE-L), Roslindale, MA; Department of Psychiatry, Harvard Medical School (GE-L, BPF), Boston, MA
2 shared publicationsHannah Heintz
Division of Geriatric Psychiatry, Geriatric Psychiatry Research Program, McLean Hospital (HH, PM, BPF), Belmont, MA
2 shared publications- Patrick Monette
Department of Anesthesiology, University of Virginia Health System, Charlottesville, Va
2 shared publications
Latest Publications
- 10 November 2020
- Published by Elsevier in General Hospital Psychiatry
- Vol. 68, 46-51
Distribution of agitation and related symptoms among hospitalized patients using a scalable natural language processing method
- 10 November 2020
- Published by Elsevier in General Hospital Psychiatry
- Vol. 68, 46-51
Distribution of agitation and related symptoms among hospitalized patients using a scalable natural language processing method
- 1 March 2020
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 28 (3) , 320-330
Emerging Collaborative Care Models for Dementia Care in the Primary Care Setting: A Narrative Review
- 1 March 2020
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 28 (3) , 320-330
Emerging Collaborative Care Models for Dementia Care in the Primary Care Setting: A Narrative Review
- 1 February 2020
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 28 (2) , 164-166
Evolving Evidence for the Efficacy and Safety of ECT for Agitation in Alzheimer Disease
- 1 February 2020
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 28 (2) , 164-166
Evolving Evidence for the Efficacy and Safety of ECT for Agitation in Alzheimer Disease
- 1 September 2019
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 27 (9) , 972-974
Establishing a Link Between Mitochondrial Dysfunction and Late-Life Depression
- 1 September 2019
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 27 (9) , 972-974
Establishing a Link Between Mitochondrial Dysfunction and Late-Life Depression
- 6 March 2019
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 27 (8) , 783-793
Lamotrigine Therapy and Biomarkers of Cerebral Energy Metabolism in Older Age Bipolar Depression
- 6 March 2019
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 27 (8) , 783-793
Lamotrigine Therapy and Biomarkers of Cerebral Energy Metabolism in Older Age Bipolar Depression
- Open Access
- 1 February 2018
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 26 (2) , 150-159
Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study
- 1 February 2018
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 26 (2) , 150-159
Open AccessSafety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study
- 2 November 2017
- Published by Taylor & Francis in International Review of Psychiatry
- Vol. 29 (6) , 597-617
Application of magnetic resonance spectroscopy in geriatric mood disorders
The prevalence of mood disorders in the rapidly-growing older adult population merits attention due to the likelihood of increased medical comorbidities, risk of hospitalization or institutionalization, and strains placed on caregivers and healthcare providers. Magnetic resonance spectroscopy (MRS) quantifies biochemical compounds in vivo, and has been used specifically for analyses of neural metabolism and bioenergetics in older adults with mood disorders, usually via proton or phosphorous spectroscopy. While yet to be clinically implemented, data gathered from research subjects may help indicate potential biomarkers of disease state or trait or putative drug targets. Three prevailing hypotheses for these mood disorders are used as a framework for the present review, and the current biochemical findings within each are discussed with respect to particular metabolites and brain regions. This review covers studies of MRS in geriatric mood disorders and reveals persisting gaps in research knowledge, especially with regard to older age bipolar disorder. Further MRS work, using higher field strengths and larger sample sizes, is warranted in order to better understand the neurobiology of these prevalent late-life disorders.
- 2 November 2017
- Published by Taylor & Francis in International Review of Psychiatry
- Vol. 29 (6) , 597-617
Application of magnetic resonance spectroscopy in geriatric mood disorders
The prevalence of mood disorders in the rapidly-growing older adult population merits attention due to the likelihood of increased medical comorbidities, risk of hospitalization or institutionalization, and strains placed on caregivers and healthcare providers. Magnetic resonance spectroscopy (MRS) quantifies biochemical compounds in vivo, and has been used specifically for analyses of neural metabolism and bioenergetics in older adults with mood disorders, usually via proton or phosphorous spectroscopy. While yet to be clinically implemented, data gathered from research subjects may help indicate potential biomarkers of disease state or trait or putative drug targets. Three prevailing hypotheses for these mood disorders are used as a framework for the present review, and the current biochemical findings within each are discussed with respect to particular metabolites and brain regions. This review covers studies of MRS in geriatric mood disorders and reveals persisting gaps in research knowledge, especially with regard to older age bipolar disorder. Further MRS work, using higher field strengths and larger sample sizes, is warranted in order to better understand the neurobiology of these prevalent late-life disorders.
- 15 May 2017
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 25 (9) , 1017-1018
Editorial Comment: Running Out of Time: Clock Copying as a Psychometric to Predict Mortality in Vulnerable Older Adults?
- 15 May 2017
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 25 (9) , 1017-1018
Editorial Comment: Running Out of Time: Clock Copying as a Psychometric to Predict Mortality in Vulnerable Older Adults?
- 19 January 2016
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 18 (2) , 1-7
Update on SSRI Treatment for Neuropsychiatric Symptoms of Dementia
Neuropsychiatric symptoms (NPS) of dementia including agitation, depression, and psychosis are common and debilitating facets of the disease process. Despite the significant impact of these symptoms on both individuals with dementia and their caregivers, safe and effective treatment options are lacking. From a pharmacological approach, antipsychotics have historically been the treatment of choice, but these medications are only modestly effective with significant adverse effects. Behavioral and psychosocial interventions have been shown to be effective but are difficult to implement in routine clinical practice. SSRI medications have been investigated as an alternative psychopharmacological approach based on evidence that the serotoninergic system is involved in the etiology of NPS in dementia. The evidence base for using SSRI medications in the treatment of NPS is growing, but the applicability of research findings to the utility of SSRIs in general in routine clinical practice is not entirely clear at this point. Further studies of a variety of SSRI medications in targeting NPS are needed to make a more definitive assessment of the efficacy of these medications in the relief of NPS.
- 19 January 2016
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 18 (2) , 1-7
Update on SSRI Treatment for Neuropsychiatric Symptoms of Dementia
Neuropsychiatric symptoms (NPS) of dementia including agitation, depression, and psychosis are common and debilitating facets of the disease process. Despite the significant impact of these symptoms on both individuals with dementia and their caregivers, safe and effective treatment options are lacking. From a pharmacological approach, antipsychotics have historically been the treatment of choice, but these medications are only modestly effective with significant adverse effects. Behavioral and psychosocial interventions have been shown to be effective but are difficult to implement in routine clinical practice. SSRI medications have been investigated as an alternative psychopharmacological approach based on evidence that the serotoninergic system is involved in the etiology of NPS in dementia. The evidence base for using SSRI medications in the treatment of NPS is growing, but the applicability of research findings to the utility of SSRIs in general in routine clinical practice is not entirely clear at this point. Further studies of a variety of SSRI medications in targeting NPS are needed to make a more definitive assessment of the efficacy of these medications in the relief of NPS.